|1.||Macdonald, R Loch: 19 articles (09/2015 - 11/2008)|
|2.||Raabe, Andreas: 8 articles (01/2013 - 06/2005)|
|3.||Ibrahim, George M: 6 articles (09/2015 - 01/2012)|
|4.||Ilodigwe, Don: 6 articles (07/2013 - 10/2010)|
|5.||Mayer, Stephan A: 5 articles (01/2013 - 07/2011)|
|6.||Vajkoczy, Peter: 4 articles (01/2013 - 07/2005)|
|7.||Frey, Aline: 4 articles (01/2013 - 11/2008)|
|8.||Wanke, Isabel: 3 articles (01/2013 - 07/2011)|
|9.||Bach, Doris: 3 articles (01/2013 - 07/2011)|
|10.||Kassell, Neal: 3 articles (01/2013 - 07/2011)|
07/01/2005 - "In Part A, treatment with clazosentan resulted in a reduced incidence of angiographically evident cerebral vasospasm (40% compared with 88% of patients, p = 0.008). "
01/01/2007 - "All 12 patients treated at our institution in the context of a phase IIa, multicenter, randomized trial on clazosentan's safety and efficacy in reducing the incidence of angiographic cerebral vasospasm were included in this substudy. "
07/01/2005 - "This study indicates that clazosentan reduces the frequency and severity of cerebral vasospasm following severe aneurysmal SAH with the incidence and severity of adverse events comparable to that of placebo."
06/01/2005 - "Clazosentan is a selective ET(A) receptor antagonist that provides for the first time clinical proof that ET-1 is involved in the pathogenesis of cerebral vasospasm. "
01/01/2011 - "Clazosentan: prevention of cerebral vasospasm and the potential to overcome infarction."
|2.||Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage)
07/01/2013 - "Clazosentan therapy after aneurysmal subarachnoid hemorrhage (SAH) has been found to be effective in reducing the incidence of vasospasm in randomized controlled trials. "
07/01/2013 - "Dissociation of vasospasm-related morbidity and outcomes in patients with aneurysmal subarachnoid hemorrhage treated with clazosentan: a meta-analysis of randomized controlled trials."
01/01/2013 - "We report here results of a randomized, double-blind, placebo-controlled study ( http://www.ClinicalTrials.gov , NCT00558311) that investigated the effect of clazosentan (5 mg/h, n = 768) or placebo (n = 389) administered for up to 14 days in patients with aneurysmal subarachnoid hemorrhage (SAH) repaired by surgical clipping. "
06/01/2012 - "Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling."
01/01/2012 - "Effect of clazosentan in patients with aneurysmal subarachnoid hemorrhage: a meta-analysis of randomized controlled trials."
|3.||Brain Injuries (Brain Injury)
03/01/2011 - "Furthermore, clazosentan treatment was effective in significantly improving behavioral outcome following traumatic brain injury. "
03/01/2011 - "Collectively, these results indicate that clazosentan, given at 30 minutes post-traumatic brain injury, is effective in improving outcome following injury."
03/01/2011 - "Our results indicate that 1·0 mg/kg clazosentan was effective in ameliorating hypoperfusion seen after traumatic brain injury. "
10/26/1998 - "In this study, we have examined the effects of the endothelin receptor subtype A antagonist, Ro 61-1790, on acute cortical neuronal injury and delayed neuronal death in the cerebellum after mild traumatic brain injury. "
03/01/2011 - "Clazosentan, a novel endothelin A antagonist, improves cerebral blood flow and behavior after traumatic brain injury."
07/01/2013 - "The objective of this meta-analysis was to determine whether clazosentan treatment after aneurysmal SAH significantly reduced the incidence of DINDs and delayed cerebral infarctions and improved outcomes. "
07/01/2013 - "The results of the present meta-analysis show that treatment with clazosentan after aneurysmal SAH significantly reduced the incidence of the vasospasm-related DINDs and delayed cerebral infarctions, but did not improve poor neurological outcomes in patients with aneurysmal SAH. "
07/01/2013 - "The meta-analysis demonstrated a significant decrease in the incidence of DINDs (relative risk [RR] 0.76 [95% CI 0.62-0.92]) and delayed cerebral infarction (RR 0.79 [95% CI 0.63-1.00]) in patients treated with clazosentan after aneurysmal SAH. "
07/01/2013 - "However, while vasospasm-related morbidity, including delayed ischemic neurological deficits (DINDs) and delayed cerebral infarctions, was consistently decreased, statistical significance was not demonstrated and outcomes were not affected by clazosentan treatment. "
03/01/2006 - "Clazosentan, an endothelin ETA antagonist, is under development by Actelion (formerly Axovan), under license from F Hoffman-La Roche, for the potential prevention of cerebral infarction and ischemia induced by cerebral vasospasm following subarachnoid hemorrhage. "
06/01/2013 - "The Clazosentan to Overcome Neurological Ischemia and Infarct Occurring after Subarachnoid Hemorrhage study was also published and unfortunately did not demonstrate an overall favorable long-term functional outcome rate for patients with aneurysmal subarachnoid hemorrhage receiving clazosentan. "
10/01/2010 - "Data from CONSCIOUS-1 (Clazosentan to Overcome Neurological Ischemia and Infarct Occurring After Subarachnoid Hemorrhage study), a dose-finding study of clazosentan, were used. "
09/01/2015 - "A post hoc analysis of perioperative complications from the Clazosentan to Overcome Neurological iSChemia and Infarction Occurring after Subarachnoid hemorrhage (CONSCIOUS-1) study was performed. "
08/01/2013 - "Exploratory analysis was performed on 413 patients enrolled in CONSCIOUS-1 (Clazosentan to Overcome Neurological Ischemia and Infarction Occurring after Subarachnoid Hemorrhage), a prospective randomized trial of clazosentan for the prevention of angiographic vasospasm. "
07/01/2013 - "This study was a post hoc exploratory analysis of the Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1) trial, a randomized, double-blind, placebo-controlled trial of 413 patients with aneurysmal SAH. "
|1.||Endothelin Receptors (Endothelin Receptor)
|6.||Endothelin A Receptor
|7.||Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)
|8.||Urokinase-Type Plasminogen Activator (Urokinase)